Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Leases: 2019-2025

Historic Current Leases for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $2.3 million.

  • Fulcrum Therapeutics' Current Leases rose 10.03% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 10.03%. This contributed to the annual value of $2.2 million for FY2024, which is 0.27% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Current Leases stood at $2.3 million for Q3 2025, which was up 2.40% from $2.3 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Current Leases high stood at $2.7 million for Q1 2023, and its period low was $469,000 during Q1 2021.
  • Moreover, its 3-year median value for Current Leases was $2.2 million (2025), whereas its average is $2.3 million.
  • Its Current Leases has fluctuated over the past 5 years, first surged by 454.80% in 2022, then decreased by 23.70% in 2024.
  • Fulcrum Therapeutics' Current Leases (Quarterly) stood at $469,000 in 2021, then spiked by 454.80% to $2.6 million in 2022, then decreased by 15.76% to $2.2 million in 2023, then declined by 0.27% to $2.2 million in 2024, then grew by 10.03% to $2.3 million in 2025.
  • Its Current Leases was $2.3 million in Q3 2025, compared to $2.3 million in Q2 2025 and $2.2 million in Q1 2025.